Biogen Price Target Raised to $191

Wedbush analysts increase price objective on biotech company's stock

Apr. 1, 2026 at 1:42pm

Got story updates? Submit your updates here. ›

Investment firm Wedbush has raised its price target on Biogen (NASDAQ:BIIB) stock from $187 to $191, maintaining a 'neutral' rating on the biotechnology company's shares. The new target price represents a potential upside of 4.04% from Biogen's previous closing price.

Why it matters

Biogen is a major player in the biotech industry, particularly in the development of treatments for neurological and neurodegenerative diseases. Analyst price target adjustments can influence investor sentiment and trading activity around the company's stock.

The details

In a research note, Wedbush analysts cited Biogen's recent financial performance and product pipeline as factors behind the price target increase. The firm currently has a 'neutral' rating on Biogen's stock.

  • Wedbush issued the updated price target and rating on Wednesday, April 1, 2026.

The players

Wedbush

An investment firm that covers Biogen and has raised its price target on the company's stock.

Biogen

A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Biogen's stock price responds to Wedbush's updated price target in the coming trading sessions.

The takeaway

Analyst price target adjustments can influence investor sentiment around biotech stocks like Biogen, which is a closely watched player in the neurology and neurodegenerative disease treatment space.